Cancer Biomarker Discovery: The Case for Pharma OutSourcing from a Dx PerspectiveThursday, 12 September 2013 at 14:45  Add to Calendar ▼2013-09-12 14:45:002013-09-12 15:45:00Europe/LondonCancer Biomarker Discovery: The Case for Pharma OutSourcing from a Dx PerspectiveExosomes and Circulating Biomarkers Summit 2013 in San Diego, CASan Diego, CASELECTBIOenquiries@selectbiosciences.comCancer therapeutic development is hard. Really hard. The successes have been few and far between. Many companies are looking to identify and incorporate biomarkers as part of their development plan. However, while companies often fixate on simple, “kittable” markers, the more powerful markers of the future—driven by leveraging NGS capabilities—will likely be complex. Identifying these markers requires niche expertise that can be provided only by companies with deep experience in this area. It is for this reason, combined with the costs that make outsourcing cancer biomarker discovery a necessity for today’s pharma companies. |
Add to Calendar ▼2013-09-12 00:00:002013-09-13 00:00:00Europe/LondonExosomes and Circulating Biomarkers Summit 2013Exosomes and Circulating Biomarkers Summit 2013 in San Diego, CASan Diego, CASELECTBIOenquiries@selectbiosciences.com
